Neuravi
Treatment of acute ischemic stroke.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | €15.0m | Debt | |
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 129 % | 175 % | 36 % | 48 % | - | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (152 %) | 20 % | 7 % | 31 % | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (117 %) | 16 % | 3 % | 31 % | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 62 % | - | - | - | - | - | - |
Source: Company filings or news article, Dealroom estimates
Related Content
Neuravi, an Irish company acquired by Johnson & Johnson, specializes in the development of medical devices for the treatment of acute ischemic stroke. The company's primary focus is on neurointerventional devices that are used to remove blood clots from the brain, a procedure known as a thrombectomy. Their product portfolio is a result of extensive research into the properties of blood clots and the mechanics of their removal.
The company's business model is centered around the research, development, and commercialization of these highly specialized medical devices. They target the global market for stroke care, with a particular focus on hospitals and specialized stroke centers that have the capabilities to perform endovascular procedures. Neuravi's revenue is generated through the sale of its devices to these healthcare providers.
The company was founded in 2009 and established a strong reputation in the field of stroke care, which ultimately led to its acquisition. This has allowed for the integration of Neuravi's technology into a larger global healthcare company, thereby expanding its reach and impact on stroke treatment worldwide.
Keywords: medical devices, stroke care, thrombectomy, neurointerventional, endovascular, blood clot removal, ischemic stroke, healthcare, medical technology, neurovascular